Previous 10 | Next 10 |
Gainers: Global Blood Therapeutics ( GBT ) +33% . Yellow ( YELL ) +27% . Pactiv Evergreen ( PTVE ) +17% . Minerva Neurosciences ( NERV ) +13% . MercadoLibre ( MELI ) +13% . Losers: Poseida Therapeutics ( PSTX ) ...
Minerva Neurosciences press release (NASDAQ:NERV): Q1 GAAP EPS of -$0.23 misses by $0.05. Cash, cash equivalents, and restricted cash as of March 31, 2022 and December 31, 2021 were approximately $55.0 million and $60.9 million, respectively. For further details see: Minerva Neuroscienc...
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the ...
Biopharmaceutical company Minerva Neurosciences (NASDAQ:NERV) has received the official meeting minutes from the March type C meeting with the U.S. FDA regarding the development of the company's compound roluperidone to treat negative symptoms in schizophrenia. The meeting's primary purp...
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS) disorders, announced today that it has received the official meeting minutes from the Type...
Minerva Neurosciences press release (NASDAQ:NERV): Q4 GAAP EPS of -$0.50 misses by $0.31. Cash, equivalents and restricted cash as of December 31, 2021 were approximately $60.9 million, as compared to $25.5 million at December 31, 2020. For further details see: Minerva Neurosciences GAA...
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today reported key business updates and financial results fo...
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that results from the Phase 3 clinical trial of r...
Minerva Neurosciences, Inc. (NERV) Q3 2021 Results Earnings Conference Call November 8, 2021, 08:30 AM ET Company Participants Geoff Race - President Remy Luthringer - Chief Executive Officer Frederick Ahlholm - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Thom...
Minerva Neurosciences (NASDAQ:NERV): Q3 GAAP EPS of -$0.22 misses by $0.01 Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2021 were approximately $65.7M. Shares +9.67% PM Press Release For further details see: Minerva Neurosciences EPS mi...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...